Becton, Dickinson and Co. | BDX - Gross Profit On Sales


Becton, Dickinson and Co. reported $2.15B in Gross Profit on Sales for its fiscal quarter ending in March of 2026.





Gross Profit On Sales Change Date
Abbott USD 5.86B 675M Mar/2026
Agilent USD 990M 44M Mar/2026
Align Technology USD 736.59M 53M Mar/2026
AngioDynamics USD 44.78M 2.93M Sep/2025
Avanos Medical USD 94.2M 8.2M Mar/2026
Baxter International USD 891M 314M Mar/2026
Becton, Dickinson and Co. USD 2.15B 257M Mar/2026
Bio-Rad Laboratories USD 345.2M 1.8M Dec/2025
Boston Scientific USD 3.61B 64M Mar/2026
Cooper Companies USD 735.4M 40.2M Mar/2026
Danaher USD 3.59B 375M Mar/2026
Dentsply International USD 427M 16M Mar/2026
Dexcom USD 750.3M 42.4M Mar/2026
Edwards Lifesciences USD 1.29B 59.4M Mar/2026
Globus Medical USD 496.26M 39.69M Mar/2026
Insulet USD 540.8M 27.8M Mar/2026
Integra LifeSciences USD 213.21M 3.89M Mar/2026
Intuitive Surgical USD 1.83B 73.8M Mar/2026
J&J USD 17.24B 642M Mar/2026
Masimo USD 250.8M 3.5M Mar/2026
Medtronic USD 6.01B 595M Mar/2026
Solventum Corp USD 1.1B 70M Mar/2026
Stryker USD 3.81B 675M Mar/2026
Tandem Diabetes Care USD 167.46M 33.17M Dec/2025
Teleflex USD 307.43M 21K Mar/2026
Terumo JPY 149.02B 4.17B Mar/2026
Thermo Fisher Scientific USD 4.49B 146M Mar/2026
Zimmer Biomet Holdings USD 1.27B 8.1M Dec/2025